2倍做多NVO ETF-Defiance(NVOX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVOX 2倍做多NVO ETF-Defiance

盘前交易 03-17 09:07:09 EDT

10.72

+0.31

+2.98%

盘前10.79

+0.07+0.65%

09:01 EDT

最高10.75	最低10.32	成交量75.59万
今开10.38	昨收10.41	日振幅4.13%
总市值4,650万	流通市值4,650万	总股本433.81万
成交额796.27万	换手率17.42%	流通股本433.81万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVOX","market":"US","secType":"STK","nameCN":"2倍做多NVO ETF-Defiance","latestPrice":10.72,"timestamp":1773691200000,"preClose":10.41,"halted":0,"volume":755890,"hourTrading":{"tag":"盘前","latestPrice":10.79,"preClose":10.72,"latestTime":"09:01 EDT","volume":9272,"amount":99015.5721,"timestamp":1773752468756,"change":0.07,"changeRate":0.00653,"amplitude":0.01959},"delay":0,"changeRate":0.029779058597502447,"floatShares":4338101,"shares":4338101,"eps":0,"marketStatus":"盘前交易","change":0.31,"latestTime":"03-17 09:07:09 EDT","open":10.38,"high":10.75,"low":10.32,"amount":7962686.61143,"amplitude":0.041306,"askPrice":10.8,"askSize":700,"bidPrice":10.78,"bidSize":660,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773754200000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":10.72,"sharesOutstanding":4128101,"nav":10.42,"aum":45203012.42,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":10.79,"preClose":10.72,"latestTime":"09:01 EDT","volume":9272,"amount":99015.5721,"timestamp":1773752468756,"change":0.07,"changeRate":0.00653,"amplitude":0.01959},"postHourTrading":{"tag":"盘后","latestPrice":10.72,"preClose":10.72,"latestTime":"19:53 EDT","volume":13108,"amount":140304.8924,"timestamp":1773705228898,"change":0,"changeRate":0,"amplitude":0.008396},"volumeRatio":0.48030656114125203,"impliedVol":0.7631,"impliedVolPercentile":0.3896},"requestUrl":"/m/hq/s/NVOX","defaultTab":"news","newsList":[{"id":"2618138250","title":"Hims & Hers Health(HIMS)盘前涨8% 日前与诺和诺德建立新的合作伙伴关系","url":"https://stock-news.laohu8.com/highlight/detail?id=2618138250","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618138250?lang=zh_cn&edition=full","pubTime":"2026-03-12 18:08","pubTimestamp":1773310089,"startTime":"0","endTime":"0","summary":"金吾财讯 | Hims & Hers Health 盘前涨8%，截至发稿，报27.950美元。消息面上，日前，Hims & Hers Health与诺和诺德建立新的合作伙伴关系，专注于提供品牌药物。两家公司于周一表示，诺和诺德已同意在Hims & Hers Health平台上销售其王牌药物Ozempic和Wegovy，其中包括备受欢迎的Wegovy口服片剂。同时，诺和诺德将撤回上个月针对Hims & Hers Health提起的诉讼。作为回报，Hims & Hers Health表示将不再为其仿制版诺和诺德药物投放广告。但如果医生认为患者有必要使用，该公司仍将销售Wegovy和Ozempic的复配版本。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/ZTgzYzFjMzMwYjg4MjEzNTY0MzUzNDIy.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZTgzYzFjMzMwYjg4MjEzNTY0MzUzNDIy.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"297963","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BZ1G4Q59.USD","BK4196","BK4588","BK4599","HIMS","LU1093756325.SGD","HIMY","LU1093756168.USD","BK4532","HIMZ","BK4007","LU0154236417.USD","HMYY","NVOX","IE00BKVL7J92.USD","HIYY","NVOH"],"gpt_icon":0},{"id":"2618157119","title":"FDA 连发多份 CRL，开年大批新药上市申请已遭拒","url":"https://stock-news.laohu8.com/highlight/detail?id=2618157119","media":"制药网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618157119?lang=zh_cn&edition=full","pubTime":"2026-03-11 14:39","pubTimestamp":1773211194,"startTime":"0","endTime":"0","summary":"2026年以来，全球医药企业就遭遇了FDA的CRL风暴。2月14日消息，Disc Medicine备受瞩目的候选药物Bitopertin用于治疗罕见血液病红细胞生成性卟啉症的上市申请遭到FDA拒绝。2月3日，阿斯利康公告称，美国FDA就Saphnelo用于成人系统性红斑狼疮患者皮下给药的生物制品许可申请发出完整答复函，驳回了其狼疮治疗药物的自行注射剂型上市申请。总的来说，2026 年 开年以来，已有众多新药上市申请被拒。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311144149a6b747a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311144149a6b747a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4530","NVOH","NVOX","INCY","LU0757428866.USD","AZN","BK4532","IE00BKVL7J92.USD","BK4007","NVO","BK4585","LU0154236417.USD","LU0390134368.USD","IE00BZ1G4Q59.USD","LU1093756168.USD","BK4121","LU0128526141.USD","LU1815336091.USD","LU1093756325.SGD","BK4599","LU0029874061.USD","IE00BFMHRM44.USD","REGN","BK4588"],"gpt_icon":0},{"id":"2618963769","title":"诺和诺德旗下“问题”工厂，又一家药企遭殃","url":"https://stock-news.laohu8.com/highlight/detail?id=2618963769","media":"生物制药小编","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618963769?lang=zh_cn&edition=full","pubTime":"2026-03-11 09:20","pubTimestamp":1773192018,"startTime":"0","endTime":"0","summary":"这也是第三家因为该工厂生产设施问题而遭发CRL的药企，其中再生元最为倒霉，2025年，有两款药物皆是因其被拒。2025年10月，同样因为这家工厂的合规性问题，再生元旗下的另一款药物—预填充注射器版本HD Eylea的补充上市申请也遭到拒批，收到FDA的CRL。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311093344a45fc34a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311093344a45fc34a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0154236417.USD","BK4007","LU1093756168.USD","NVO","LU1093756325.SGD","BK4588","IE00BKVL7J92.USD","NVOX","NVOH","IE00BZ1G4Q59.USD","BK4532","BK4585","BK4599"],"gpt_icon":1},{"id":"2618895342","title":"Hims & Hers与诺和诺德达成和解","url":"https://stock-news.laohu8.com/highlight/detail?id=2618895342","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618895342?lang=zh_cn&edition=full","pubTime":"2026-03-10 21:03","pubTimestamp":1773147780,"startTime":"0","endTime":"0","summary":"Hims & Hers与诺和诺德结束诉讼，Hims将停止推广复方胰高血糖素样肽-1药物，并通过其平台提供威戈维和奥泽匹克；Hims股价大涨。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-10/doc-inhqphnh6182604.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HIMS","BK4599","LU1093756325.SGD","IE00BKVL7J92.USD","NVOH","BK4588","BK4585","IE00BZ1G4Q59.USD","BK4532","LU0154236417.USD","LU1093756168.USD","NVO","BK4007","NVOX"],"gpt_icon":0},{"id":"2618933958","title":"跨国药企2025年成绩单：“药王”易主，创新资产交易创新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2618933958","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618933958?lang=zh_cn&edition=full","pubTime":"2026-03-10 17:04","pubTimestamp":1773133472,"startTime":"0","endTime":"0","summary":"随着跨国药企陆续披露2025年业绩报告，全球制药行业的新一轮竞争格局逐步清晰。业绩榜单中，强生以全球941.93亿美元的总营收斩获榜首，旗下创新制药和医疗科技两大核心业务板块分别收入604.01亿美元（+6%）和337.92亿美元（+6.1%）；礼来凭借44%的高增速，实现651.79亿美元的全年营收，成为增速最快的头部药企。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603103667509930.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603103667509930.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0130517989.USD","IE00BKVL7J92.USD","BK4516","NVO","GSKH","LU0266013472.USD","MRK","IE00BN8TJ469.HKD","LU2125154778.USD","LU2361045086.USD","IE00BJJMRZ35.SGD","LU1989772840.SGD","SG9999014575.USD","NVOX","GSK","LU1571399168.USD","BK4559","LU1093756325.SGD","SGXZ57979304.SGD","LU0477156953.USD","GSK.UK","IE00BLSP4452.SGD","BK4585","LU0320765489.SGD","NVOH","CDE","LU0648001328.SGD","LU1023059063.AUD","LU0203347892.USD","LU1057294990.SGD","LU1066051811.HKD","LU1934455863.HKD","LU1291159041.SGD","LU2324357040.USD","01477","LU1983299246.USD","LU2361044865.SGD","LU0868494617.USD","IE00B1BXHZ80.USD","LU0098860793.USD","LU0289739699.SGD","LU1223082519.USD","SG9999001176.USD","LU1066051225.USD","BK4588","SG9999014542.SGD","SG9999015358.SGD","BK4550","LU2360032135.SGD","BK4534"],"gpt_icon":1},{"id":"2618147987","title":"花旗上调Hims & Hers Health(HIMS.US)评级至“中性” 看好诺和诺德协议下的合规溢价","url":"https://stock-news.laohu8.com/highlight/detail?id=2618147987","media":"智通财经","labels":["executive","rating"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618147987?lang=zh_cn&edition=full","pubTime":"2026-03-10 16:07","pubTimestamp":1773130046,"startTime":"0","endTime":"0","summary":"花旗银行在最新的研究报告中对这一合作给予了高度评价，并将其视为 Hims & Hers 发展史上的重要转折点。花旗分析师指出，通过引入官方正版药物，Hims & Hers 成功摆脱了长期困扰其业务模式的合规性阴影与法律风险。这一利好消息在二级市场引发了剧烈反弹，Hims & Hers 的股价在消息公布后的交易时段内一度飙升超过 35%，周一收涨40.79%，报22.16美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":"5cccc8ba7a9e8bd0cd40ca1f6c5f84c3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412108.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,rating","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4559","LU0130517989.USD","LU1093756325.SGD","LU0106831901.USD","LU2125154935.USD","LU1244550221.USD","LU2456880835.USD","LU2125154778.USD","BK4599","LU0314106906.USD","BK4196","LU1366192091.USD","LU1267930227.SGD","HMYY","LU0648001328.SGD","LU2360032135.SGD","LU0980610538.SGD","LU1668664300.SGD","LU1093756168.USD","BK4207","HIYY","NVOX","LU0477156953.USD","LU1791807156.HKD","BK4566","LU0128525689.USD","BK4007","HIMZ","BK4532","LU0310800965.SGD","LU2417539215.USD","IE00BKVL7J92.USD","LU1162221912.USD","BK4534","HIMS","LU0320765646.SGD","IE00BSNM7G36.USD","LU2462157665.USD","LU0072461881.USD","LU0052756011.USD","LU0154236417.USD","LU2236285917.USD","HIMY","LU0162691827.USD","BK4504","LU1201861249.SGD","LU0170899867.USD","LU0098860793.USD","BK4585","LU1506573853.SGD","LU1244550494.USD","NVOH","LU0130102774.USD","BK4588","LU1244550577.SGD","IE00BZ1G4Q59.USD"],"gpt_icon":1},{"id":"2618672446","title":"3月10日美股成交额前20：HIMS与诺和诺德达成合作，股价大涨逾40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618672446","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618672446?lang=zh_cn&edition=full","pubTime":"2026-03-10 04:48","pubTimestamp":1773089280,"startTime":"0","endTime":"0","summary":"周一美股成交额第1名英伟达收高2.72%，成交313.6亿美元。亿万富豪廖凯原周一再度增持英伟达，将其持股数量翻倍至200万股。　　摩尔维持对博通的“买入”评级，将其目标价从462美元上调至470美元，意味着约42%的上涨空间。　　此外，3月2日，英伟达宣布投资20亿美元并与Lumentum达成多年战略合作，包括数十亿美元采购高端激光元件的承诺，聚焦AI数据中心光学技术。　　该消息公布后，诺和诺德撤销了对该公司的诉讼，标志着双方争端的结束。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2125f643a531f294312a5aa84a9983ad","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-10/doc-inhqmumf6558599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HIMZ","LU1093756168.USD","NVOH","LU0154236417.USD","LU1093756325.SGD","NVO","NVOX","BK4588","IE00BZ1G4Q59.USD","BK4585","HIMY","BK4196","IE00BKVL7J92.USD","BK4599","HIMS","BK4007","BK4532","HIYY","HMYY"],"gpt_icon":1},{"id":"2618781516","title":"诺和诺德盘中异动 股价大涨3.00%报39.74美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618781516","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618781516?lang=zh_cn&edition=full","pubTime":"2026-03-10 00:15","pubTimestamp":1773072908,"startTime":"0","endTime":"0","summary":"北京时间2026年03月10日00时15分，诺和诺德股票出现异动，股价急速拉升3.00%。截至发稿，该股报39.74美元/股，成交量1310.03万股，换手率0.29%，振幅3.21%。诺和诺德股票所在的制药行业中，整体跌幅为0.48%。诺和诺德公司简介：诺和诺德在全球品牌糖尿病治疗市场中占据大约三分之一的份额，是世界上领先的糖尿病护理产品供应商。诺和诺德还拥有一个生物制药部门，专注于治疗血友病和其他疾病的蛋白质疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310001508a6b30ca2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310001508a6b30ca2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NVO","LU0154236417.USD","BK4585","LU1093756325.SGD","LU1093756168.USD","BK4532","BK4588","IE00BKVL7J92.USD","NVOX","IE00BZ1G4Q59.USD","NVOH","BK4599"],"gpt_icon":1},{"id":"2618621200","title":"分析师：Hims & Hers本身不会通过诺和诺德的GLP-1s药物盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=2618621200","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618621200?lang=zh_cn&edition=full","pubTime":"2026-03-09 21:43","pubTimestamp":1773063796,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4532","BK4007","IE00BKVL7J92.USD","BK4144","BK4585","LU1093756168.USD","BK4588","BK4590","IE00BZ1G4Q59.USD","LU0154236417.USD","LU1093756325.SGD","BK4599","NVOX","HIMS","NVOH"],"gpt_icon":0},{"id":"1162171962","title":"Hims与诺和诺德合作或引发短期逆风——市场快讯","url":"https://stock-news.laohu8.com/highlight/detail?id=1162171962","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162171962?lang=zh_cn&edition=full","pubTime":"2026-03-09 20:53","pubTimestamp":1773060828,"startTime":"0","endTime":"0","summary":"早盘8点49分——Hims & Hers Health Inc.股价因诺和诺德终止对其诉讼并达成合作的消息而大幅飙升。根据协议，Hims平台将引入诺和诺德的GLP-1类药物。Truist分析师指出，尽管此举消除了Hims面临的重要法律风险，但合作可能对其短期业务造成冲击。\n作为协议的一部分，Hims将停止销售复合GLP-1药物，而这类药物曾贡献其大部分营收。不过，品牌GLP-1药物的收入持续性显著更高，尤其考虑到Hims的复合药物此前一直面临法律威胁。分析师认为，这一转变可能促使投资者愿意给予Hims更高估值倍数。受此影响，Hims股价在盘前交易中猛涨51%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2125f643a531f294312a5aa84a9983ad","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","NVOH","BK4585","BK4588","HIMS","HMYY","LU1093756325.SGD","NVOX","IE00BKVL7J92.USD","BK4007","HIMZ","LU0154236417.USD","IE00BZ1G4Q59.USD","HIYY","HIMY","BK4196","LU1093756168.USD","BK4532"],"gpt_icon":0},{"id":"2618356626","title":"诺和诺德确认将在HIMS & HERS平台上销售WEGOVY、OZEMPIC产品。","url":"https://stock-news.laohu8.com/highlight/detail?id=2618356626","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618356626?lang=zh_cn&edition=full","pubTime":"2026-03-09 20:31","pubTimestamp":1773059515,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2125f643a531f294312a5aa84a9983ad","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["HIMY","LU0154236417.USD","NVOH","BK4599","IE00BKVL7J92.USD","BK4007","LU1093756325.SGD","HMYY","LU1093756168.USD","HIMS","HIMZ","IE00BZ1G4Q59.USD","BK4532","BK4585","BK4588","NVOX","BK4196","HIYY","NVO"],"gpt_icon":0},{"id":"2617656092","title":"Hims & Hers Health美股盘后涨近37%，报道称诺和诺德计划在Hims的平台上销售其减肥药","url":"https://stock-news.laohu8.com/highlight/detail?id=2617656092","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617656092?lang=zh_cn&edition=full","pubTime":"2026-03-07 08:48","pubTimestamp":1772844525,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2125f643a531f294312a5aa84a9983ad","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4588","NVOX","IWN","LU0154236417.USD","IWO","TNA","BK4534","HIMS","UWM","NVO","LU1093756168.USD","TWM","MNQmain","RWM","BK4585","TZA","BK4007","NVOH","BK4581","BK4535","BK4599","SRTY","BK4532","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU1093756325.SGD","BK4550"],"gpt_icon":0},{"id":"2617262656","title":"诺和诺德和HIMS将共同销售减肥药，结束双方的争端。","url":"https://stock-news.laohu8.com/highlight/detail?id=2617262656","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617262656?lang=zh_cn&edition=full","pubTime":"2026-03-07 08:34","pubTimestamp":1772843680,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2125f643a531f294312a5aa84a9983ad","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["HIMZ","LU1093756325.SGD","BK4196","HIMY","BK4588","BK4585","NVO","HIYY","HIMS","BK4599","IE00BKVL7J92.USD","NVOH","BK4532","LU0154236417.USD","HMYY","LU1093756168.USD","IE00BZ1G4Q59.USD","NVOX","BK4007"],"gpt_icon":0},{"id":"2617463761","title":"速递｜一针一周的组合拳：IcoSema在华获批，诺和诺德把胰岛素和GLP-1装进同一支笔","url":"https://stock-news.laohu8.com/highlight/detail?id=2617463761","media":"GLP1减重宝典","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617463761?lang=zh_cn&edition=full","pubTime":"2026-03-06 23:24","pubTimestamp":1772810690,"startTime":"0","endTime":"0","summary":"整理 | GLP1减重宝典内容团队3月6日，国家药监局官网信息显示，诺和诺德的依柯胰岛素司美格鲁肽注射液 IcoSema 在中国获批上市，用于2型糖尿病治疗。IcoSema由两种活性成分组成。两者在中国此前都已分别获批上市，如今用复方形式打包，意味着诺和诺德把周制剂胰岛素的便利性与GLP-1的代谢收益，直接做成一条更省事的治疗路径。IcoSema的商业逻辑就在这里：把加用胰岛素和加用GLP-1这两步，尽量合并成一步，减少决策成本和执行成本。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603070219219543bc6a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603070219219543bc6a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BKVL7J92.USD","LU1093756325.SGD","BK4144","LU1093756168.USD","BK4590","NVOX","BK4599","LU0154236417.USD","BK4585","NVO","NVOH","BK4007","BK4532","BK4588","IE00BZ1G4Q59.USD"],"gpt_icon":1},{"id":"2617831166","title":"今日，诺和诺德 GLP-1 联合制剂国内获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2617831166","media":"丁香园 Insight 数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617831166?lang=zh_cn&edition=full","pubTime":"2026-03-06 15:50","pubTimestamp":1772783431,"startTime":"0","endTime":"0","summary":"3 月 6 日，NMPA 官网显示，诺和诺德“依柯胰岛素+司美格鲁肽-IcoSema”在国内获批上市。根据公开信息和临床试验进展，Insight 数据库推断本次获批的适应症为用于在饮食和运动的基础上，接受基础胰岛素或 GLP-1 受体激动剂治疗控制不佳的成人 2 型糖尿病患者的治疗。2025 年 11 月，该药获欧洲药品管理局批准上市，用于治疗成人 2 型糖尿病，成为全球首个基础胰岛素 GLP-1RA 周制剂。胰岛素剂量方面，相较于依柯胰岛素组，IcoSema 组胰岛素剂量显著减少。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306161755a6aa2ba6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306161755a6aa2ba6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BKVL7J92.USD","BK4532","LU0154236417.USD","NVOH","BK4585","BK4588","BK4599","BK4144","BK4007","IE00BZ1G4Q59.USD","NVOX","BK4590","LU1093756325.SGD","NVO","LU1093756168.USD"],"gpt_icon":1},{"id":"2617577411","title":"诺和诺德“司美格鲁肽”治疗MASH拟纳入优先审评，即将惠及国内广大MASH患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2617577411","media":"药研途","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617577411?lang=zh_cn&edition=full","pubTime":"2026-03-06 07:28","pubTimestamp":1772753310,"startTime":"0","endTime":"0","summary":"2026年3 月 3 日，CDE 官网显示，诺和诺德“司美格鲁肽注射液”新适应症在国内申报上市，并拟纳入优先审评，适应症为：用于治疗代谢相关脂肪性肝炎伴中重度肝纤维化的非肝硬化成人患者。全球约有2.5亿MASH患者，其中超过三分之一的超重或肥胖人群同时患有MASH，疾病负担日益加重。司美格鲁肽治疗MASH的作用机制司美格鲁肽通过多重直接与间接途径改善MASH病理进程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306074632a4518566&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306074632a4518566&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0154236417.USD","LU1093756168.USD","NVO","BK4599","NVOX","BK4532","BK4007","IE00BZ1G4Q59.USD","NVOH","LU1093756325.SGD","BK4588","IE00BKVL7J92.USD","BK4585"],"gpt_icon":1},{"id":"2617254074","title":"礼来瞄准雇主GLP-1覆盖 以与诺和诺德竞争","url":"https://stock-news.laohu8.com/highlight/detail?id=2617254074","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617254074?lang=zh_cn&edition=full","pubTime":"2026-03-05 21:39","pubTimestamp":1772717940,"startTime":"0","endTime":"0","summary":"礼来公司推出“Employer Connect”，为新型多剂量Zepbound提供每月449美元的净价格，并与Teladoc Health和GoodRx等合作伙伴整合，以扩大肥胖药物的可及性；诺和诺德仍是主要竞争对手。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-05/doc-inhpycce3059268.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2168563687.JPY","BK4532","IE00BJJMRZ35.SGD","LU1145028129.USD","BK4144","SG9999015986.USD","LU0787776722.HKD","LU0353189680.USD","BK4588","IE00BFSS7M15.SGD","IE00BJT1NW94.SGD","LU2108987350.USD","IE00BN29S564.USD","NVOX","LLYX","LU2361045086.USD","SG9999013999.USD","LU1988902786.USD","LU2896262040.SGD","LU0786609619.USD","LU2417539215.USD","SG9999015952.SGD","LU0203202063.USD","LU0882574055.USD","SGXZ31699556.SGD","LU0109394709.USD","LU1868836914.USD","LU1291159041.SGD","IE00BFSS8Q28.SGD","LU0238689110.USD","LU0823416689.USD","LU1623119135.USD","LU2324357040.USD","LU2211815571.USD","LU2756315318.SGD","LU2168564495.EUR","IE00BJLML261.HKD","LU1057294990.SGD","LU0471298694.HKD","LU1868837136.USD","LU2756315664.SGD","LU0158827948.USD","LU1814569148.SGD","LU0943347566.SGD","LU1983299246.USD","LU0094547139.USD","BK4581","LU2237443622.USD","LU0109391861.USD","IE00BJJMRY28.SGD","LU2237443895.HKD","LLY","IE0001KFT4U8.USD","LU1868836757.USD","LU2456880835.USD","LU2461242641.AUD","LU0689472784.USD","SG9999001176.USD","SG9999015978.USD","LU0466842654.USD","IE00BFTCPJ56.SGD","SG9999014906.USD","LU2264538146.SGD","LU0456855351.SGD","LU0432979614.USD","LU2028103732.USD","LU2087625088.SGD","LU1323610961.USD","ELIL","LU0256863902.USD","LU1023059063.AUD","LU0114720955.EUR","SG9999018857.SGD","LU2236285917.USD","LLII","LU2750360997.AUD","BK4516","BK4534","IE00B4JS1V06.HKD","LLYZ","LU0640476718.USD","LU0820561909.HKD","LU2089984988.USD","LU2361044865.SGD","LU0708995401.HKD","LU2602419157.SGD","LU0203201768.USD","IE00BK4W5L77.USD","LU0061475181.USD","LU1917777945.USD","LU2023250504.SGD","SGXZ81514606.USD","BK4599","ELIS","BK4533","SG9999001176.SGD","LU1093756168.USD","BK4007","LU1366192091.USD","LU2491050154.USD","IE00B1BXHZ80.USD","LU0058720904.USD","LU2471134952.CNY","LU2552382058.USD","LU0323591593.USD","LU1551013342.USD","LU2471134796.USD","LU0823434740.USD","LU2361044949.HKD","LU2471134523.USD","LU1629891620.HKD","LU1868837300.USD","LU0320765059.SGD","LU2089284900.SGD","LU2271345857.HKD","LU2468319806.SGD","LU0882574139.USD","LU0096364046.USD","IE00B7KXQ091.USD","IE0005OL40V9.USD","LU1989771016.USD","LU2746668461.USD","LU0353189763.USD","LU2237443465.HKD","LU2357305700.SGD","SG9999018865.SGD","IE00BJJMRX11.SGD","LU1232071149.USD","LU1280957306.USD","LU2491050071.SGD","LU2462157665.USD","LU1804176565.USD","LU0079474960.USD","LU2265009873.SGD","LU0234572021.USD","IE00B1XK9C88.USD","LU2471134879.HKD","LU1035775433.USD","LU1064131342.USD","SG9999017495.SGD","LU1267930730.SGD","BK4590","LU0889565916.HKD","LU1551013425.SGD","LU1868836591.USD","SG9999014914.USD","LU1548497426.USD","LU0256863811.USD","LU0417517546.SGD","LU1720051017.SGD","LU1061106388.HKD","LU2750360641.GBP","LU2746668974.SGD","LU2168564222.USD","IE00BZ1G4Q59.USD","IE0009355771.USD","LU2106854487.HKD","LU1093756325.SGD","LU0210536198.USD","LU0672654240.SGD","LU0097036916.USD","LU0106261372.USD","IE00B775H168.HKD","LU2112291526.USD","IE00B4R5TH58.HKD","LU0320765992.SGD","LU2552382132.HKD","IE00BKPKM429.USD","LU2111349929.HKD","LU0820562030.AUD","LU0154236417.USD","LU0820561818.USD","LU2168564149.EUR","LU0158827781.USD","IE00B2B36J28.USD","IE00BKDWB100.SGD","SG9999015945.SGD","IE00BWXC8680.SGD","NVOH","LU2237443382.USD","LU0122379950.USD","LU1974910355.USD","LU2089283258.USD","SG9999014898.SGD","LU1712237335.SGD","SGXZ99366536.SGD","NVO","LU0316494557.USD","SGXZ57979304.SGD","SGXZ51526630.SGD","LU0266013472.USD","LU2237443549.SGD","LU0354030511.USD","IE0004445239.USD","IE0002141913.USD","LU1127390331.HKD","SG9999014880.SGD","LU0385154629.USD","LU0683600562.USD","LU0289739699.SGD","LU2491049909.HKD","IE00BK4W5M84.HKD","LU0964807845.USD","LU0823434583.USD","LU2063271972.USD","LU2360106947.USD","LU2237438978.USD","LU0006306889.USD","BK4585","IE00BKVL7J92.USD","LU1069344957.HKD","LU2213496289.HKD","LU2023250330.USD","LU2552382215.SGD","GB00BDT5M118.USD","LU0225283273.USD","IE0004445015.USD","LU2168564065.EUR","LU0471298777.SGD","LU2023251221.USD","LU2237443978.SGD","LU0198837287.USD","LU1720051108.HKD","LU0354030438.USD"],"gpt_icon":0},{"id":"2617959547","title":"诺和诺德、武田、默克等齐换帅，中国市场进入战略新周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2617959547","media":"动脉网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617959547?lang=zh_cn&edition=full","pubTime":"2026-03-05 09:53","pubTimestamp":1772675580,"startTime":"0","endTime":"0","summary":"2026年以来，诺和诺德、武田、默克等多家跨国药企相继完成中国区“换帅”。费森尤斯卡比中国宣布张巍3月2日加入，4月3日起任总裁兼董事长，她拥有超二十年医药行业经验；罗杰仁2月1日起任默克中国总裁，1月1日起兼任默克生命科学中国负责人，在医药健康和生命科学领域经验丰富；穆安德2月1日起任默克中国医药健康业务董事总经理，他是内部提拔晋升而来；诺和诺德中国宣布周霞萍3月31日离任，蔡琰同日接任大中国区总裁，周霞萍助力公司10款新药获批上市，蔡琰是资深管理者；1月底武田制药任命刘燕为武田中国总裁，负责整体战略和业务发展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305100816a6a46605&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305100816a6a46605&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2125154935.USD","SG9999013999.USD","LU0203347892.USD","LU0985320562.USD","LU0868494708.USD","LU0980610538.SGD","LU1989772840.SGD","LU2023250504.SGD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU1093756168.USD","BK4516","LU0289739699.SGD","LU0203345920.USD","LU1989771016.USD","LU2112291526.USD","LU0320765646.SGD","LU2125154778.USD","LU0208291251.USD","LU1069347547.HKD","IE0009355771.USD","LU0106261372.USD","IE000M9KFDE8.USD","LU1037948541.HKD","SG9999002224.SGD","BK4533","LU0265550946.USD","LU1023059063.AUD","MCHI","IE00BJT1NW94.SGD","LU0130102774.USD","BK4588","BK4599","LU0238689110.USD","IE00BBT3K403.USD","LU2461242641.AUD","BK4585","LU0965508806.USD","SG9999014559.SGD","IE00B1BXHZ80.USD","LU1093756325.SGD","LU0477156953.USD","LU0965509101.SGD","LU1057294990.SGD","LU2023250843.SGD","ASHS","ASHR","LU1162221912.USD","LU1917777945.USD","LU1066051498.USD","SG9999015358.SGD","LU2089984988.USD","SG9999015341.SGD","LU1941712264.USD","LU1201861249.SGD","LU1934455863.HKD","IE0002141913.USD","NVOH","LU2324357040.USD","CQQQ","CWEB","LU0861579265.USD","LU2106854487.HKD","TAK","LU1929549753.HKD","IE00BLSP4452.SGD","SG9999001440.SGD","SG9999014567.USD","LU0006306889.USD","IE00BLSP4239.USD","IE00BN8TJ469.HKD","LU1699723380.USD","LU1037948897.HKD","NVO","DRAG","LU0130517989.USD","BK4504","LU2361045086.USD","LU1066053197.SGD","LU1291159041.SGD","LU1116320737.USD","BK4532","LU0234572021.USD","LU0965509010.AUD","LU0320765489.SGD","LU0965509283.SGD","LU1061106388.HKD","LU1989772923.USD","LU0211331839.USD","KWEB","SG9999002232.USD","IE00BJJMRZ35.SGD","IE00BKVL7J92.USD","LU1974910355.USD","SG9999001176.USD","LU0868494617.USD","SGXZ57979304.SGD","LU1066051225.USD","NVOX","LU0648001328.SGD","LU0963586101.USD","LU0070302665.USD","SG9999001176.SGD","LU0154236417.USD","LU1983299246.USD","LU0432979614.USD","LU1934455194.USD","LU0098860793.USD","LU1430594728.SGD","LU2361044865.SGD","LU0265550359.USD","BK4559","LU1934455277.USD","BK4534","LU1571399168.USD","LU0942090050.USD","BK4614","BK4007","LU0122379950.USD","MRK","LU0266013472.USD","IE00BZ1G4Q59.USD","LU1585245621.USD","LU2360032135.SGD","IE00BSNM7G36.USD","LU2361044949.HKD","IE00BFTCPJ56.SGD","LU2468319806.SGD","LU1116320901.HKD","LU1941712348.USD","SG9999014542.SGD","BK4550","SG9999014575.USD","LU0058720904.USD","LU1035773651.USD","LU1066051811.HKD"],"gpt_icon":0},{"id":"2616034538","title":"大摩下调诺和诺德目标价至40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616034538","media":"中金财经","labels":["rating"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616034538?lang=zh_cn&edition=full","pubTime":"2026-03-04 16:57","pubTimestamp":1772614622,"startTime":"0","endTime":"0","summary":"摩根士丹利将诺和诺德的目标价从42美元下调至40美元，评级则从“减持”上调“持股观望”。(格隆汇)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260304/32044400.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"rating","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK4007","NVO","LU0154236417.USD","BK4585","LU1093756325.SGD","LU1093756168.USD","BK4532","BK4588","IE00BKVL7J92.USD","NVOX","IE00BZ1G4Q59.USD","NVOH","BK4599"],"gpt_icon":0},{"id":"2616582066","title":"速递｜FDA重拳出击，30家远程医疗公司因虚假宣传复合GLP-1产品遭警告","url":"https://stock-news.laohu8.com/highlight/detail?id=2616582066","media":"GLP1减重宝典","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616582066?lang=zh_cn&edition=full","pubTime":"2026-03-04 15:02","pubTimestamp":1772607756,"startTime":"0","endTime":"0","summary":"整理 | GLP1减重宝典内容团队美国食品药品监督管理局于 3月3日 正式宣布，向30家远程医疗公司发出了警告信，指责这些公司在其官方网站上对复合GLP-1产品存在虚假或误导性宣传。违规行为包括声称复合制剂与FDA批准的原研药“相同”，以及以远程医疗公司名称或商标推广药品，暗示其为合规的配药商。据了解，在过去6个月内，FDA已经向数千家制药公司及远程医疗公司发出警告，要求撤除误导性广告。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304154137a44a31f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304154137a44a31f1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0154236417.USD","LU1093756168.USD","NVO","BK4599","NVOX","BK4532","LLY","BK4007","IE00BZ1G4Q59.USD","NVOH","LU1093756325.SGD","BK4588","IE00BKVL7J92.USD","BK4585","BK4590","BK4144"],"gpt_icon":1}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0678},{"period":"1month","weight":-0.4328},{"period":"3month","weight":-0.4776},{"period":"6month","weight":-0.6608},{"period":"1year","weight":-0.846},{"period":"ytd","weight":-0.5103}],"compareEarnings":[{"period":"1week","weight":-0.0136},{"period":"1month","weight":-0.0187},{"period":"3month","weight":-0.0145},{"period":"6month","weight":0.0149},{"period":"1year","weight":0.1887},{"period":"ytd","weight":-0.0189}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"exchange":"ARCA","name":"2倍做多NVO ETF-Defiance","nameEN":"Defiance Daily Target 2X Long NVO ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"2倍做多NVO ETF-Defiance(NVOX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供2倍做多NVO ETF-Defiance(NVOX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"2倍做多NVO ETF-Defiance,NVOX,2倍做多NVO ETF-Defiance股票,2倍做多NVO ETF-Defiance股票老虎,2倍做多NVO ETF-Defiance股票老虎国际,2倍做多NVO ETF-Defiance行情,2倍做多NVO ETF-Defiance股票行情,2倍做多NVO ETF-Defiance股价,2倍做多NVO ETF-Defiance股市,2倍做多NVO ETF-Defiance股票价格,2倍做多NVO ETF-Defiance股票交易,2倍做多NVO ETF-Defiance股票购买,2倍做多NVO ETF-Defiance股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"2倍做多NVO ETF-Defiance(NVOX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供2倍做多NVO ETF-Defiance(NVOX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}